<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cencora Inc. — News on 6ix</title>
<link>https://6ix.com/company/cencora-inc</link>
<description>Latest news and press releases for Cencora Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cencora-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835585178dffbe2df0ea8d4.webp</url>
<title>Cencora Inc.</title>
<link>https://6ix.com/company/cencora-inc</link>
</image>
<item>
<title>Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives</title>
<link>https://6ix.com/company/cencora-inc/news/soleo-health-appoints-joy-rowan-as-new-senior-vice-president-of-sales-to-drive-strategic-growth-initiatives</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/soleo-health-appoints-joy-rowan-as-new-senior-vice-president-of-sales-to-drive-strategic-growth-initiatives</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>FRISCO, Texas, April 16, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, today announced the appointment of Joy Rowan, MS, MBA to the role of senior vice president, sales. Reporting to the chief commercial officer, Rowan will lead the Company’s field sales organization to accelerate commercial performance and deliver on its strategic growth initiatives. With over 25 years of industry experience and a proven track record of</description>
</item>
<item>
<title>Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling</title>
<link>https://6ix.com/company/cencora-inc/news/dario-appoints-veteran-healthcare-executive-john-r-palumbo-to-board-of-directors-to-support-accelerated-commercial-scaling-1</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/dario-appoints-veteran-healthcare-executive-john-r-palumbo-to-board-of-directors-to-support-accelerated-commercial-scaling-1</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors. The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling.</description>
</item>
<item>
<title>Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-announces-date-and-time-for-second-quarter-fiscal-2026-earnings-release-2</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-announces-date-and-time-for-second-quarter-fiscal-2026-earnings-release-2</guid>
<pubDate>Wed, 01 Apr 2026 20:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., April 01, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026.</description>
</item>
<item>
<title>Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners-retina-business</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners-retina-business</guid>
<pubDate>Mon, 23 Mar 2026 11:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., March 23, 2026--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora’s Retina Consultants of America ("RCA"), a leading management services organization (MSO).</description>
</item>
<item>
<title>Cencora Announces Financial Leadership Transition</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-announces-financial-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-announces-financial-leadership-transition</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., March 17, 2026--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.</description>
</item>
<item>
<title>Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics</title>
<link>https://6ix.com/company/cencora-inc/news/gallant-announces-first-of-its-kind-partnership-with-mwi-animal-health-to-deliver-anticipated-fda-conditionally-approved-stem-cell-therapy-into-veterinary-clinics</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/gallant-announces-first-of-its-kind-partnership-with-mwi-animal-health-to-deliver-anticipated-fda-conditionally-approved-stem-cell-therapy-into-veterinary-clinics</guid>
<pubDate>Fri, 27 Feb 2026 15:38:00 GMT</pubDate>
<description>Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced a landmark fulfillment agreement with MWI Animal Health (MWI), part of global healthcare company Cencora, to create the first-ever ultra-low temperature cold chain for veterinary medicine. This comes as Gallant advances toward delivering the potential first-ever FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Admini</description>
</item>
<item>
<title>Covetrus and MWI Animal Health to Merge</title>
<link>https://6ix.com/company/cencora-inc/news/covetrus-and-mwi-animal-health-to-merge</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/covetrus-and-mwi-animal-health-to-merge</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa. & PORTLAND, Maine, February 18, 2026--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform.</description>
</item>
<item>
<title>Cencora Closes $3.0 Billion Senior Notes Offering</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-closes-3-0-billion-211500836</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-closes-3-0-billion-211500836</guid>
<pubDate>Fri, 13 Feb 2026 21:15:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., February 13, 2026--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% S</description>
</item>
<item>
<title>Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-prices-500-million-3-221500515</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-prices-500-million-3-221500515</guid>
<pubDate>Tue, 10 Feb 2026 22:15:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., February 10, 2026--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due Februar</description>
</item>
<item>
<title>Cencora Reports Fiscal 2026 First Quarter Results</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-reports-fiscal-2026-first-113000371</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-reports-fiscal-2026-first-113000371</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., February 04, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below</description>
</item>
<item>
<title>Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products</title>
<link>https://6ix.com/company/cencora-inc/news/curant-rare-announces-collaboration-with-cencora-to-support-commercialization-of-rare-and-orphan-drug-products</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/curant-rare-announces-collaboration-with-cencora-to-support-commercialization-of-rare-and-orphan-drug-products</guid>
<pubDate>Thu, 22 Jan 2026 14:00:00 GMT</pubDate>
<description>ATLANTA, January 22, 2026--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products.</description>
</item>
<item>
<title>Cencora Elects Ellen Cooper to Its Board of Directors</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-elects-ellen-cooper-board-123000017</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-elects-ellen-cooper-board-123000017</guid>
<pubDate>Thu, 22 Jan 2026 12:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., January 22, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026.</description>
</item>
<item>
<title>Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-announces-date-time-first-213000641</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-announces-date-time-first-213000641</guid>
<pubDate>Tue, 06 Jan 2026 21:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., January 06, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.</description>
</item>
<item>
<title>RIS Rx Appoints Leslie Donato to Board of Directors</title>
<link>https://6ix.com/company/cencora-inc/news/ris-rx-appoints-leslie-donato-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/ris-rx-appoints-leslie-donato-to-board-of-directors</guid>
<pubDate>Mon, 22 Dec 2025 15:00:00 GMT</pubDate>
<description>IRVINE, Calif., December 22, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Leslie Donato to its Board of Directors.</description>
</item>
<item>
<title>Cencora Finalizes Agreement to Acquire TPG's Equity Interest in OneOncology</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-finalizes-agreement-acquire-tpgs-122600072</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-finalizes-agreement-acquire-tpgs-122600072</guid>
<pubDate>Mon, 15 Dec 2025 12:26:00 GMT</pubDate>
<description>Cencora, Inc. today announced it has entered into a definitive agreement to acquire TPG's equity interest in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology. The transaction marks an important step for OneOncology and its practice partners, following significant physician-led investment and growth for the platform.</description>
</item>
<item>
<title>Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-accelerates-oneoncology-acquisition-extending-120000246</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-accelerates-oneoncology-acquisition-extending-120000246</guid>
<pubDate>Mon, 15 Dec 2025 12:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., December 15, 2025--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm.</description>
</item>
<item>
<title>Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-enhances-global-pharmaceutical-logistics-123000188</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-enhances-global-pharmaceutical-logistics-123000188</guid>
<pubDate>Wed, 03 Dec 2025 12:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., December 03, 2025--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Europe, expanding its global network and strengthening the specialty logistics services it can deliver to pharmaceutical companies worldwide.</description>
</item>
<item>
<title>Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-announces-1-billion-investment-120000719</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-announces-1-billion-investment-120000719</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., November 05, 2025--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution network in the United States. The investments — headlined by the opening of its second national distribution center in Ohio and an expanded presence in Alabama and California — will increase Cencora’s capacity, improve efficiency and enhance the resilience of its national distribution network, stren</description>
</item>
<item>
<title>Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results</title>
<link>https://6ix.com/company/cencora-inc/news/cencora-reports-fiscal-2025-fourth-113000511</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/cencora-reports-fiscal-2025-fourth-113000511</guid>
<pubDate>Wed, 05 Nov 2025 11:30:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., November 05, 2025--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is</description>
</item>
<item>
<title>World-Renowned Surgeon and Entrepreneur Dr. Mandeep S. Dhalla Invests in DentScribe.ai and Joins as Strategic Advisor</title>
<link>https://6ix.com/company/cencora-inc/news/world-renowned-surgeon-and-entrepreneur-dr-mandeep-s-dhalla-invests-in-dentscribeai-and-joins-as-strategic-advisor</link>
<guid isPermaLink="true">https://6ix.com/company/cencora-inc/news/world-renowned-surgeon-and-entrepreneur-dr-mandeep-s-dhalla-invests-in-dentscribeai-and-joins-as-strategic-advisor</guid>
<pubDate>Mon, 27 Oct 2025 06:12:00 GMT</pubDate>
<description>DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.</description>
</item>
</channel>
</rss>